GO:0016495 C-X3-C chemokine receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016495 (C-X3-C chemokine receptor activity) is a molecular function defined as combining with a C-X3-C chemokine and transmitting a signal across the membrane to initiate a change in cell activity.
• The canonical receptor for this activity is CX3CR1, which binds the chemokine CX3CL1 (fractalkine) and is best known for mediating neuron-microglia communication.
• CX3CR1 signaling is implicated in aging, Alzheimer's disease, neuroinflammation, depression, spinal cord injury, and hyper-IgE syndrome [2,4,5,6].
• The CX3CL1-CX3CR1 axis activates downstream pathways including JAK2-STAT3, and its activity is modulated by kinases such as LRRK2 [4,8].
• CX3CR1 expression is a key marker of microglia, NK cells, and NKT cells, and its regulation by STAT3 influences immune cell differentiation.
• CRISPR-based knockout, knock-in, and overexpression models are essential tools for dissecting CX3CR1 function in health and disease [4,6].
Description
C-X3-C chemokine receptor activity (GO:0016495) is a molecular function that enables a cell to bind a C-X3-C chemokine and convert that binding event into an intracellular signal. This activity is central to the communication between neurons and microglia in the central nervous system, where the chemokine CX3CL1 (fractalkine) engages its receptor CX3CR1 to regulate microglial activation, migration, and neuroinflammatory responses. Because dysregulated CX3CR1 signaling is increasingly linked to age-related cognitive decline, neurodegenerative disease, and immune disorders, researchers need robust experimental systems to study this receptor's function [2,4,5]. Understanding GO:0016495 at the molecular, cellular, and organismal levels is therefore critical for developing targeted interventions. This article synthesizes current knowledge from QuickGO and peer-reviewed literature to provide a research-grade overview of the term, its associated genes, disease relevance, and state-of-the-art methods for its study.
C-X3-C chemokine receptor activity At A Glance
| GO ID | GO:0016495 |
|---|---|
| GO term | C-X3-C chemokine receptor activity |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding a C-X3-C chemokine and transmitting a signal across the membrane to initiate a change in cell activity |
| Cognate ligand | C-X3-C chemokine (e.g., CX3CL1/fractalkine) |
| Primary receptor | CX3CR1 |
| Associated diseases | Alzheimer's disease, neuroinflammation, depression, spinal cord injury, hyper-IgE syndrome |
| Research methods | CRISPR knockout/knock-in, single-cell RNA sequencing, bulk RNA sequencing, pharmacological inhibition |
What Is GO:0016495?
According to the Gene Ontology, C-X3-C chemokine receptor activity (GO:0016495) is defined as combining with a C-X3-C chemokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. A C-X3-C chemokine is characterized by three amino acids between the first two cysteines of the characteristic four-cysteine motif. In simpler terms, this activity describes how a receptor protein on the cell surface recognizes a specific chemokine ligand and triggers a signaling cascade inside the cell.
Why Is C-X3-C chemokine receptor activity Important in Cell Biology?
C-X3-C chemokine receptor activity is a critical molecular function that bridges the immune and nervous systems. The CX3CL1-CX3CR1 axis is one of the key pathways controlling microglial surveillance and neuroinflammation, and its dysregulation has been implicated in the pathogenesis of Alzheimer's disease, aging-related cognitive decline, depression, and spinal cord injury [2,4,6]. Beyond the brain, CX3CR1 signaling influences the differentiation and function of natural killer (NK) and NKT cells, with mutations in STAT3 leading to altered CX3CR1 expression in hyper-IgE syndrome. The receptor's activity is also modulated by kinases such as LRRK2, linking it to Parkinson's disease biology. Because of its broad physiological impact, GO:0016495 is a high-value target for both basic research and therapeutic development.
• Mediates neuron-microglia communication via the CX3CL1-CX3CR1 axis.
• Regulates microglial activation and neuroinflammation in aging and Alzheimer's disease.
• Influences adult hippocampal neurogenesis and is implicated in depression.
• Modulates NK and NKT cell differentiation through STAT3-dependent regulation of CX3CR1.
• Plays a protective role in spinal cord injury via lactate-mediated lactylation of microglia-related proteins.
• Is regulated by LRRK2, a kinase linked to Parkinson's disease.
• Inhibition of mPGES-1 enhances CX3CL1 expression, affecting resolution of acute inflammation.
• Serves as a biomarker candidate in aging and age-related diseases.
• Is a potential therapeutic target for ocular allergy and dry eye disease.
• Provides a molecular handle for CRISPR-based functional genomics in immune and neural cells [4,6].
What Happens During C-X3-C chemokine receptor activity?
Ligand Binding and Receptor Activation
In simple terms: The chemokine CX3CL1 binds to the CX3CR1 receptor on the cell surface, like a key fitting into a lock.
C-X3-C chemokine receptor activity begins with the specific binding of a C-X3-C chemokine, such as CX3CL1 (fractalkine), to its receptor CX3CR1. This interaction is highly selective due to the unique three-amino-acid spacing between the first two cysteines of the chemokine motif. Upon binding, the receptor undergoes conformational changes that enable it to act as a guanine nucleotide exchange factor for heterotrimeric G proteins, initiating intracellular signaling.
Intracellular Signal Transduction
In simple terms: Once the receptor is activated, it triggers a relay race of signals inside the cell.
Activated CX3CR1 couples to G proteins and stimulates downstream effectors, including the JAK2-STAT3 pathway. In microglia, this signaling cascade promotes the release of pro-inflammatory cytokines and modulates cell migration and phagocytosis. The signaling is tightly regulated; for example, LRRK2 modulates microglial activity through regulation of CX3CR1-mediated signaling pathways.
Cellular Responses and Physiological Outcomes
In simple terms: The signal leads to changes in how the cell behaves, such as moving, releasing factors, or altering its activity.
CX3CR1 signaling in microglia influences neuroinflammation, synaptic pruning, and neuronal survival. In the context of aging and Alzheimer's disease, neuronal cathepsin S increases neuroinflammation and causes cognitive decline via the CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway. In NK and NKT cells, STAT3 regulates their differentiation through CX3CR1, highlighting the receptor's role in immune cell development. Additionally, lactate-mediated lactylation of microglia-related proteins can protect against spinal cord injury by modulating these responses.
Resolution and Feedback Regulation
In simple terms: The cell has ways to turn off or adjust the signal to prevent excessive inflammation.
The activity of C-X3-C chemokine receptors is subject to feedback regulation. Inhibition of mPGES-1 attenuates efficient resolution of acute inflammation by enhancing CX3CL1 expression, suggesting that the CX3CL1-CX3CR1 axis is involved in the resolution phase. This feedback ensures that inflammation is properly resolved and tissue homeostasis is maintained.
Key Genes Involved in GO:0016495 C-X3-C chemokine receptor activity
The following genes and proteins are directly associated with C-X3-C chemokine receptor activity (GO:0016495) and its signaling network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CX3CR1 | Receptor for CX3CL1; mediates chemotaxis and adhesion | Central to neuroinflammation, microglial function, and immune cell differentiation [4,5] |
| CX3CL1 | Sole ligand for CX3CR1; exists as membrane-bound and soluble forms | Key mediator of neuron-microglia communication; implicated in inflammation resolution [4,7] |
| STAT3 | Transcription factor downstream of CX3CR1; regulates NK/NKT differentiation | Mutations cause hyper-IgE syndrome with altered CX3CR1 expression |
| JAK2 | Kinase that phosphorylates STAT3 in CX3CR1 signaling | Part of the JAK2-STAT3 pathway activated by CX3CL1-CX3CR1 |
| LRRK2 | Kinase that modulates microglial activity via CX3CR1 signaling | Linked to Parkinson's disease; regulates chemokine receptor signaling |
| CTSS | Cathepsin S; neuronal protease that increases neuroinflammation | Increases CX3CL1-CX3CR1 signaling in aging and Alzheimer's disease |
| mPGES-1 | Microsomal prostaglandin E synthase-1; regulates inflammation resolution | Its inhibition enhances CX3CL1 expression |
| IL-6 | Cytokine that can be induced by CX3CR1 signaling | Involved in neuroinflammatory responses |
| TNF-alpha | Pro-inflammatory cytokine modulated by CX3CR1 activity | Contributes to neuroinflammation in disease models |
| IL-1beta | Cytokine released by activated microglia | Downstream of CX3CR1 signaling in neuroinflammation |
| CD11b | Microglial activation marker | Used to assess microglial responses in CX3CR1 studies |
| GFAP | Astrocyte activation marker | Indirectly affected by CX3CR1-mediated neuroinflammation |
| BDNF | Neurotrophic factor involved in hippocampal neurogenesis | Linked to CX3CR1 signaling in depression models |
| NLRP3 | Inflammasome component activated in microglia | Modulated by CX3CL1-CX3CR1 axis |
| Iba1 | Microglia/macrophage marker | Used to quantify microglial density in CX3CR1 studies |
| CX3CR1+ cells | Subpopulation of immune cells expressing CX3CR1 | Identified by flow cytometry in NK/NKT differentiation studies |
How Is C-X3-C chemokine receptor activity Regulated?
The activity of C-X3-C chemokine receptors is regulated at multiple levels. Transcriptional regulation of CX3CR1 is controlled by STAT3, as shown in hyper-IgE syndrome where STAT3 mutations lead to altered CX3CR1 expression and impaired NK/NKT cell differentiation. Post-translational modifications, such as phosphorylation by LRRK2, modulate CX3CR1-mediated signaling pathways in microglia. Additionally, the availability of the ligand CX3CL1 is regulated by proteases and inflammatory mediators; inhibition of mPGES-1 enhances CX3CL1 expression, thereby affecting the resolution of acute inflammation. Lactate-mediated lactylation of microglia-related proteins also modulates CX3CR1 signaling in the context of spinal cord injury.
C-X3-C chemokine receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CX3CR1 | Alzheimer's disease, neuroinflammation | CX3CR1 knockout mice; microglial cell lines with CRISPR knockout |
| CX3CR1 | Hyper-IgE syndrome | Patient-derived cells with STAT3 mutations; CRISPR knock-in of STAT3 mutations |
| CX3CL1 | Acute inflammation resolution | mPGES-1 inhibitor-treated models; CX3CL1 overexpression |
| LRRK2 | Parkinson's disease | LRRK2 mutant microglia; CRISPR point mutation |
| CX3CR1 | Spinal cord injury | Lactate-treated microglia; CX3CR1 knockout rats |
Alzheimer's Disease and Aging
The CX3CL1-CX3CR1 axis is a key mediator of neuroinflammation in aging and Alzheimer's disease. Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via the CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway. This pathway represents a potential therapeutic target for slowing cognitive decline. Additionally, CX3CR1 is considered a frailty biomarker candidate from genes and pathways regulated in aging and age-related diseases.
Depression and Adult Hippocampal Neurogenesis
Microglia play a critical role in adult hippocampal neurogenesis, and their function is regulated by CX3CR1 signaling. In depression, dysregulated microglial activity via CX3CR1 may impair neurogenesis, contributing to mood disorders. Targeting the CX3CL1-CX3CR1 axis is being explored as a therapeutic strategy for depression.
Spinal Cord Injury
Lactate-mediated lactylation of microglia-related proteins has protective effects on spinal cord injury, and this protection involves modulation of CX3CR1 signaling. Single-cell RNA sequencing integrated with bulk RNA sequencing has revealed these protective mechanisms, highlighting the therapeutic potential of targeting CX3CR1 in spinal cord injury.
Hyper-IgE Syndrome and Immune Disorders
STAT3 regulates NK and NKT cell differentiation through CX3CR1, and mutations in STAT3 cause hyper-IgE syndrome with impaired NK/NKT cell development. This links C-X3-C chemokine receptor activity directly to primary immunodeficiency. Additionally, CX3CL1 and CX3CR1 are biomarkers of ocular allergy and dry eye disease.
From C-X3-C chemokine receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CX3CR1 loss affect microglial activation? | CX3CR1 knockout mice or CRISPR-Cas9 knockout in BV-2 microglial cells |
| How do STAT3 mutations alter CX3CR1 expression? | CRISPR knock-in of STAT3 mutations in NK/NKT cells |
| What is the effect of CX3CR1 overexpression on neuroinflammation? | Lentiviral overexpression of CX3CR1 in primary microglia |
| Can LRRK2 point mutations modulate CX3CR1 signaling? | CRISPR point mutation (e.g., G2019S) in LRRK2 in microglial cells |
| How does CX3CL1-CX3CR1 signaling affect spinal cord injury? | CX3CR1 knockout rats treated with lactate |
| What is the role of CX3CR1 in NK/NKT cell differentiation? | CRISPR knockout of CX3CR1 in human NK cells |
How to Study the C-X3-C chemokine receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR-Cas9 knockout | Loss of gene function | Studying CX3CR1 requirement in microglial activation |
| Single-cell RNA sequencing | Transcriptomic profiles at single-cell resolution | Identifying CX3CR1+ cell populations in spinal cord injury |
| Bulk RNA sequencing | Global gene expression changes | Analyzing pathways downstream of CX3CR1 |
| Flow cytometry | Cell surface protein expression | Quantifying CX3CR1+ NK/NKT cells |
| Immunofluorescence | Protein localization and cell morphology | Assessing microglial activation in brain tissue |
| Western blot | Protein expression and phosphorylation | Detecting JAK2-STAT3 pathway activation |
| ELISA | Cytokine secretion | Measuring CX3CL1, IL-6, TNF-alpha levels [4,7] |
| Pharmacological inhibition | Enzyme or pathway activity | Testing mPGES-1 inhibitors on CX3CL1 expression |
CRISPR-Cas9 Knockout
CRISPR-Cas9 knockout of CX3CR1 or its downstream effectors (e.g., STAT3, JAK2) is a powerful approach to dissect the function of C-X3-C chemokine receptor activity. Knockout microglial cell lines or primary cells can be used to assess changes in chemotaxis, cytokine release, and signaling pathway activation [4,5].
Single-Cell and Bulk RNA Sequencing
Single-cell RNA sequencing integrated with bulk RNA sequencing has been used to reveal the protective effects of lactate-mediated lactylation of microglia-related proteins on spinal cord injury, highlighting the role of CX3CR1 in this process. These methods allow researchers to profile CX3CR1 expression across cell types and identify downstream transcriptional changes.
Pharmacological Inhibition and Small Molecules
Inhibition of mPGES-1 attenuates efficient resolution of acute inflammation by enhancing CX3CL1 expression, demonstrating the utility of pharmacological tools to modulate the CX3CL1-CX3CR1 axis. Small molecule inhibitors of JAK2 or STAT3 can also be used to block downstream signaling.
Flow Cytometry and Immunofluorescence
Flow cytometry can quantify CX3CR1+ NK and NKT cell populations, as shown in studies of hyper-IgE syndrome. Immunofluorescence with markers such as Iba1 and GFAP can assess microglial and astrocyte activation in brain tissue from CX3CR1 knockout or overexpression models.
How CRISPR Can Be Used to Study GO:0016495 C-X3-C chemokine receptor activity
Knockout
CRISPR-Cas9 knockout of CX3CR1 or its signaling partners (e.g., JAK2, STAT3) enables researchers to determine the causal role of C-X3-C chemokine receptor activity in cellular responses. For example, CX3CR1 knockout microglia show altered neuroinflammatory profiles and impaired responses to CX3CL1. Knockout models are essential for validating drug targets and understanding disease mechanisms.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes in CX3CR1 or downstream effectors to mimic human disease variants. For instance, introducing the LRRK2 G2019S mutation in microglial cells can reveal how this kinase modulates CX3CR1-mediated signaling. Point mutations in STAT3 can also be introduced to study hyper-IgE syndrome-associated defects in NK/NKT cell differentiation.
Knock-in
CRISPR knock-in can be used to insert reporter tags (e.g., GFP, luciferase) into the CX3CR1 locus for real-time tracking of receptor expression and localization. Knock-in of human CX3CR1 into mouse models can humanize the receptor for drug testing. Additionally, knock-in of disease-associated mutations (e.g., in STAT3) allows functional studies in relevant cell types.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CX3CR1 can be used to study gain-of-function effects, such as enhanced microglial chemotaxis or increased neuroinflammation. Overexpression models are valuable for identifying downstream signaling events and for screening potential inhibitors.
How EDITGENE Supports C-X3-C chemokine receptor activity Research
Researchers studying C-X3-C chemokine receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from gene knockout to precise point mutations and overexpression, all supported by advanced bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for C-X3-C chemokine receptor activity research.
Frequently Asked Questions About C-X3-C chemokine receptor activity
What is C-X3-C chemokine receptor activity?
C-X3-C chemokine receptor activity (GO:0016495) is a molecular function where a receptor binds a C-X3-C chemokine and transmits a signal across the cell membrane to initiate a change in cell activity.
What genes are involved in C-X3-C chemokine receptor activity?
The primary gene is CX3CR1, which encodes the receptor. Its ligand is CX3CL1. Downstream signaling involves JAK2, STAT3, and is modulated by LRRK2 [4,5,8].
What diseases are associated with CX3CR1 signaling?
CX3CR1 signaling is implicated in Alzheimer's disease, aging-related cognitive decline, depression, spinal cord injury, hyper-IgE syndrome, and ocular allergy [2,3,4,5,6].
How is CX3CR1 regulated in immune cells?
STAT3 regulates CX3CR1 expression in NK and NKT cells, and mutations in STAT3 cause hyper-IgE syndrome with altered CX3CR1 levels.
What is the role of CX3CL1-CX3CR1 axis in neuroinflammation?
The CX3CL1-CX3CR1 axis mediates neuron-microglia communication and can promote or resolve neuroinflammation depending on context. Neuronal cathepsin S increases neuroinflammation via this axis in Alzheimer's disease.
How can I study C-X3-C chemokine receptor activity in the lab?
Common methods include CRISPR knockout of CX3CR1, single-cell RNA sequencing, flow cytometry, and pharmacological inhibition of downstream pathways [4,5,6,7].
What is the JAK2-STAT3 pathway's role in CX3CR1 signaling?
The JAK2-STAT3 pathway is activated downstream of CX3CL1-CX3CR1 and contributes to neuroinflammation and cognitive decline in aging and Alzheimer's disease.
Is CX3CR1 a biomarker for aging?
Yes, CX3CR1 is considered a candidate frailty biomarker from genes and pathways regulated in aging and age-related diseases.
What is the connection between LRRK2 and CX3CR1?
LRRK2 modulates microglial activity through regulation of CX3CR1-mediated signaling pathways, linking it to Parkinson's disease.
Can CRISPR be used to model CX3CR1-related diseases?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study CX3CR1 function in microglia, NK cells, and other cell types [4,5,6].
Conclusion
C-X3-C chemokine receptor activity (GO:0016495) is a fundamental molecular function that governs critical interactions between the immune and nervous systems. The CX3CL1-CX3CR1 axis is central to microglial function, neuroinflammation, and immune cell differentiation, with far-reaching implications for aging, neurodegeneration, and immunodeficiency. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate the mechanisms and therapeutic potential of this pathway.
References
- 1. Cardoso AL et al.. 2018. Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases.. Ageing Res Rev 47:214-277 PMID: 30071357
- 2. Fang S et al.. 2023. Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics.. Front Immunol 14:1193053 PMID: 37881439
- 3. Zemba M et al.. 2023. Biomarkers of ocular allergy and dry eye disease.. Rom J Ophthalmol 67(3):250-259 PMID: 37876509
- 4. Liu PP et al.. 2025. Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway in aging and Alzheimer's disease.. Aging Cell 24(2):e14393 PMID: 39453382
- 5. Liu J et al.. 2025. STAT3 regulates NK and NKT cell differentiation through C-X3-C motif chemokine receptor 1 (CX3CR1) in hyper-IgE syndrome.. Mol Biomed 6(1):104 PMID: 41212476
- 6. Zhang B et al.. 2024. Single-cell RNA sequencing integrated with bulk RNA sequencing analysis reveals the protective effects of lactate-mediated lactylation of microglia-related proteins on spinal cord injury.. CNS Neurosci Ther 30(9):e70028 PMID: 39218784
- 7. Rappl P et al.. 2021. Inhibition of mPGES-1 attenuates efficient resolution of acute inflammation by enhancing CX3CL1 expression.. Cell Death Dis 12(2):135 PMID: 33542207
- 8. Ma B et al.. 2016. LRRK2 modulates microglial activity through regulation of chemokine (C-X3-C) receptor 1 -mediated signalling pathways.. Hum Mol Genet 25(16):3515-3523 PMID: 27378696
